Epsilogen funding news – London-based Epsilogen Secures £12.5 Million in Series B Expansion Funding
Sep 9, 2024 | By Oliver Bennett

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, secures £12.5 million in series B expansion funding bringing the Series B total to £43.25 million. This financing will fund the delivery of clinical Proof of Concept for lead asset MOv18 IgE in a phase Ib trial featuring platinum-resistant ovarian cancer (PROC) as well as further development of the company’s IgE-based pipeline.
SUMMARY
- Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, secures £12.5 million in series B expansion funding bringing the Series B total to £43.25 million.
- Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer.
The financing was entirely conducted by existing investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund and ALSA Ventures.
Read also - Stockholm-based Tiptapp Raises €1 Million in Funding
MOv18 IgE has a unique mechanism of action differentiating it from other agents currently in the clinic and on the market. Key aspects of this mechanism include high affinity binding to its main cognate receptor, FcεR1, thereby enabling immunosurveillance and potent myeloid cell driven tumour cell killing. Additionally, IgE antibodies drive modulation of the tumour immune microenvironment to become more pro-inflammatory, leading to increased intra-tumoural levels of activated T cells and tumour killing macrophages.
RECOMMENDED FOR YOU
Magentic AI platform Secures $5.5M For AI-driven Savings In Tariff-hit Supply Chains
Kailee Rainse
Jul 22, 2025
Covalo Raises €3.5M To Build Data Platform For Personal Care Industry
Kailee Rainse
Apr 2, 2026
Funding Wrap of the Week | European Startups Funding Roundup | March 24 – March 29
Oliver Bennett
Mar 30, 2024
Tim Wilson, CEO of Epsilogen said “We are delighted to have received strong continued support from our existing investors and we thank them. The promise of IgE to treat cancer is based upon its unique mechanism of action and MOv18 IgE is the first ever to be tested in man. Everything is ready for phase Ib initiation which will occur shortly and we look forward to reporting progress from the trial.”
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Recommended Stories for You
Zurich’s Una Terra Closes €50M Circular Economy Growth Fund To Reduce Plastic Waste And CO2 Emissions
Kailee Rainse Sep 12, 2025
Supercede funding news – London-based Supercede Raises $15Million in a Series A Round Funding
Oliver Bennett Jun 29, 2024




